Valneva SE (VALN) Cash & Equivalents Growth (1y) (2020 - 2026)
Analysis
Valneva SE (VALN) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 28.50% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -57.58% |
| 10 | Valneva SE | 581.90 Mn | 440.64 Mn | 1.86 Mn | -22.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.64% |
| Mar 31, 2026 | -23.42% |
| Dec 31, 2025 | -29.02% |
| Sep 30, 2025 | -2.32% |
| Jun 30, 2025 | 29.03% |
| Mar 31, 2025 | -16.14% |
| Dec 31, 2024 | 32.55% |
| Sep 30, 2024 | -7.90% |
| Jun 30, 2024 | -36.42% |
| Mar 31, 2024 | -29.75% |
| Dec 31, 2023 | -53.60% |
| Sep 30, 2023 | -29.17% |
| Jun 30, 2023 | -37.96% |
| Mar 31, 2023 | -21.81% |
| Dec 31, 2022 | 638,756.95% |
| Sep 30, 2022 | -9.99% |
| Jun 30, 2022 | -9.66% |
| Mar 31, 2022 | 22.76% |
| Dec 31, 2021 | -99.98% |
| Dec 31, 2020 | 241.73% |